Cataract News and Research

Latest Cataract News and Research

Omeros commences planned PK substudy in Phase 3 clinical program of OMS302

Omeros Corporation today announced the initiation of the planned pharmacokinetic (PK) substudy in its Phase 3 clinical program evaluating OMS302 in patients undergoing intraocular lens replacement (ILR) surgery.

1 Jun 2012

Mass. Eye and Ear Cataract Master bridges gap between wet lab training and patient surgery

Phacoemulsification cataract surgery is one of the most frequently performed eye surgeries in the United States, with 1.5 million procedures performed each year. It is also one of the most complex procedures to learn. A new, highly innovative, computer-based simulation tool, the Mass. Eye and Ear Cataract Master, bridges the learning gap that residents and ophthalmologists new to phaco must navigate prior to performing actual surgery.

30 May 2012

Five-point checklist to protect eyes from sun’s harmful rays

Like your skin, overexposure to the sun can wreak havoc on your eyes. Sun damage can cause severe conditions such as sunburn to the cornea, tissue growth on the surface of eyes that can block vision, skin cancer of the eyelids and may even contribute to the development of cataracts and other eye problems.

14 May 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.

From Santen Pharmaceutical Co., Ltd. 8 May 2012

Andrew Technologies launches HydraSolve Lipoplasty System at ASAPS meeting

Andrew Technologies, LLC launched the HydraSolve Lipoplasty System today at the American Society of Aesthetic Plastic Surgery (ASAPS) in Vancouver, BC.

5 May 2012

STAAR Surgical first quarter total revenue increases 4% to $15.5M

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that sales of its Visian ICL product in the first quarter ended March 30, 2012 increased 25% to $8.6 million.

3 May 2012

IRIDEX launches non-invasive MicroPulse Laser Trabeculoplasty for glaucoma

IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).

27 Apr 2012

FDA clears Abbott’s iFS Femtosecond laser for use in cataract surgery

Abbott announced today U.S. Food and Drug Administration clearance to use its iFS Advanced Femtosecond Laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

21 Apr 2012

NHS surgery waiting times and time of discharge under scrutiny

The NHS medical director Prof Sir Bruce Keogh, has written to Strategic Health Authorities saying it is unacceptable to send people home when they may have no family support. Figures show that 100 NHS trusts sent 239,233 patients home between 23:00 and 06:00 in 2011. The Times reported that some 3.5% of all hospital discharges took place between those hours and this rate had steadily held for the past five years. The Times had contacted 170 NHS trusts in England but only 100 responded. The rates of those discharged varied widely between different hospitals.

19 Apr 2012

Asthma treatment still inadequate in Australia

Writing in the latest edition of Australian Prescriber, Associate Professor Helen Reddel, research leader at the Woolcock Institute of Medical Research says many people are prescribed higher doses than necessary. Most people do not use their inhalers correctly, leading to poor clinical outcomes and wasted medicines.

15 Apr 2012

OptiMedica's Catalys Precision Laser System receives CE mark approval

Global ophthalmic company OptiMedica Corp. has announced that its Catalys Precision Laser System has been CE mark approved for creating single-plane and multi-plane arc cuts/incisions in the cornea during cataract surgery.

12 Apr 2012

Omeros initiates enrollment in second Phase 3 trial of OMS302

Omeros Corporation today announced that patient enrollment has begun in the Company's second Phase 3 clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

10 Apr 2012

Changes in corneal thickness occur in patients at early stages of FECD

A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.

10 Apr 2012

Monitoring necessary for early intervention in Fuchs' Endothelial Corneal Dystrophy patients

10 Apr 2012

Oral fluoroquinolones increase risk of retinal detachment

In an analysis of a cohort that included nearly one million patients who had visited an ophthalmologist, patients who were taking oral fluoroquinolones had a higher risk of developing a retinal detachment, a serious eye condition, compared with nonusers, although the absolute risk was small, according to a study in the April 4 issue of JAMA.

4 Apr 2012

LensAR closes $24 million private financing

LensAR Inc., a developer of the next generation of laser systems for cataract surgery, announced the closing of a $24 million private financing which included investments from Aisling Capital and Florida Growth Fund (FGF).

12 Mar 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has received approval from the Australian Therapeutic Goods Administration (TGA) for EYLEA (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams (mg) via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

8 Mar 2012

Ivantis initiates enrollment in Hydrus Microstent study for open angle glaucoma

Ivantis announced the enrollment of the first patient in the Hydrus IV study today. The Hydrus Microstent is the world's first intracanalicular scaffold for treatment of primary open angle glaucoma, a disease that afflicts over 70 million people worldwide and approximately 3 million people in the United States.

6 Mar 2012

Survey: Americans spend more for health care than people in other countries

The report from the International Federation of Health Plans found that Americans pay more for physician time, for scans, surgery and drugs than people in other countries. Also in the news, other reports from the health care marketplace explore the lack of insurance coverage for reproductive-age women and the growth in the number of companies that are offering incentives to their employees to better manage their health.

5 Mar 2012